Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications.

Abstract

A significant number of patients with asthma remain uncontrolled despite treatment with inhaled corticosteroids (ICS) and long-acting β2 adrenergic bronchodilators (LABA). The addition of long-acting antimuscarinic agents (LAMA) can improve the management of asthma in these patients. Recently, three novel triple therapy (ICS/LABA/LAMA) formulations in a single-inhaler device (SITT) have been investigated in patients with uncontrolled asthma despite ICS/LABA treatment. Here, we review systematically the evidence available to date in relation to SITT in patients with uncontrolled asthma despite ICS-LABA treatment and conclude that SITT is a safe and effective therapeutic alternative in these patients. We also discuss how to position this new therapeutic alternative in their practical clinical management as well as the opportunities and challenges that it may generate for patients, physicians, and payers.

• Authors: Alvar Agusti, Leonardo Fabbri, Lies Lahousse, Dave Singh, Alberto Papi
• Journal: Allergy (Allergy) Vol. 77 Issue 4 Pg. 1105-1113 (04 2022) ISSN: 1398-9995 [Electronic] Denmark
• PMID: 34478578 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review, Systematic Review)
• Copyright: © 2021 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Chemical References

• Adrenal Cortex Hormones
• Adrenergic beta-2 Receptor Agonists
• Bronchodilator Agents
• Muscarinic Antagonists

Topics

• Administration, Inhalation
• Adrenal Cortex Hormones (therapeutic use)
• Adrenergic beta-2 Receptor Agonists
• Asthma (chemically induced, drug therapy)
• Bronchodilator Agents
• Drug Therapy, Combination
• Humans
• Muscarinic Antagonists (adverse effects)
• Nebulizers and Vaporizers
• Pulmonary Disease, Chronic Obstructive (drug therapy)